AbClon Registers Japanese Patent for Switchable CAR-T Receptor Antibody
Cotinine-Specific Antibody and CAR Patents Registered in Japan After South Korea
Switch Molecule Patent Registered in Six Countries
Technology Applied to AT501, a Candidate for HER2-Positive Solid Tumors
AbClon has secured a Japanese patent for receptor technology on the CAR-T cell side of its switchable CAR-T (zCAR-T) platform. Following its patent for a switch molecule that binds to cancer cells, the company has now patented the receptor that recognizes that molecule. Securing rights to a system that can turn CAR-T cells on and off through dosing could support technology licensing negotiations.
AbClon announced on October 16 that its patent for “Cotinine-Specific Antibodies and Chimeric Antigen Receptors (CARs)” had been registered in Japan. The patent was first registered in South Korea. Its companion patent for “HER2 Affibody-Based Switch Molecules” has been registered in six countries—South Korea, the United States, Canada, China, Australia and Japan—and is under review in Europe.
In conventional CAR-T therapies, the cancer-recognition receptor is fixed on T cells, so the cells remain active after a single dose. This makes side effects such as cytokine release syndrome (CRS) and neurotoxicity (ICANS) difficult to control. Another limitation is that the therapy targets only one antigen, so its effectiveness can decline if cancer cells lose that antigen.
zCAR-T uses a switch molecule between CAR-T cells and cancer cells. An affibody on one side of the switch molecule—a protein about 1/25 the size of a conventional antibody—binds to HER2 on cancer cells, while cotinine on the other side binds to CAR-T cells. The newly registered patent covers an antibody sequence that binds specifically to the stereostructure of S-cotinine. Because CAR-T cells stop working when administration of the switch molecule is discontinued, this approach can help manage side effects if they arise.
Another feature is that a single CAR-T cell can be used against different types of cancer by changing only the switch molecule. AbClon is applying the technology to AT501, a drug candidate for HER2-positive solid tumors, including ovarian, gastric and breast cancers. The company is also expanding its development to include multi-target therapies that combine several switch molecules to overcome resistance.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An AbClon official said, “For switchable CAR-T to work, both a switch that targets cancer cells and receptor technology that recognizes the switch are necessary. With patents secured for both components, we will be in a favorable position in technology licensing and co-development negotiations with global pharmaceutical companies.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.